共 50 条
Anti-apoptotic mechanisms in small-cell lung carcinoma
被引:3
|作者:
Loriot, Yohann
[1
,2
,3
,4
]
Calderaro, Julien
[2
,3
]
Soria, Jean-Charles
[1
]
Deutsch, Eric
[4
]
Vieth, Philippe
[2
,3
]
机构:
[1] Inst Gustave Roussy, Dept Med, F-94800 Villejuif, France
[2] Inst Gustave Roussy, Dept Pathol, F-94800 Villejuif, France
[3] Inst Gustave Roussy, Lab Rech Translat Module Histocytopathol, F-94800 Villejuif, France
[4] Inst Gustave Roussy, UPRES 27 10, F-94800 Villejuif, France
关键词:
BCL-2 ANTISENSE OLIGONUCLEOTIDE;
FIBROBLAST-GROWTH-FACTOR;
PROTEIN-KINASE-B;
CANCER CELLS;
FACTOR-I;
EXPRESSION;
RESISTANCE;
LINES;
INHIBITOR;
DEATH;
D O I:
10.1016/j.annpat.2009.12.005
中图分类号:
R36 [病理学];
学科分类号:
100104 ;
摘要:
Small-cell lung carcinomas account for about 15-20% of lung cancer and are characterized by an intrinsic resistance to apoptosis. Increasing evidence suggests that alteration in apoptosis/antiapoptosis balance could lead to fundamental resistance of small-cell lung cancer to chemotherapy and radiation. These molecular alterations include alteration of mitochondrial pathways (BCL2 and BCLXL overexpression, activation of stress protein such as HSP 90 and HSP70, activation of PI3K/AKT/mTOR pathway). Others abnormalities could inhibit activation of extrinsic pathway such as caspase-8 and FAS underexpression as well as C-FLIP overexpression. New therapies targeting some of these abnormalities are under clinical evaluation and predictive factors of response are needed to personnalise these therapies. (C) 2010 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:17 / 24
页数:8
相关论文